Status:
TERMINATED
Bevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration
Lead Sponsor:
Asociación para Evitar la Ceguera en México
Conditions:
Age Related Macular Degeneration
Eligibility:
All Genders
55-99 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine if of combination therapy of intravitreal bevacizumab 4 days after the application of photodynamic therapy could improve the visual outcomes of patients with ...
Detailed Description
The neovascular age related macular degeneration(AMD) is a important cause of legal blindness in adults older than 50 years. Currently the treatment is photodynamic therapy that offer stabilization an...
Eligibility Criteria
Inclusion
- 55 years old neovascular Age related acular degeneration subfoveolar neovascular membrane best corrected visual acuity better than 20/200 snellen (1.0 logMAR)
Exclusion
- Previously treated eyes glaucoma diabetes mellitus uncontrolled hypertension coronary artery disease
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2007
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00347399
Start Date
March 1 2006
End Date
June 30 2007
Last Update
May 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Luis Sanchez Bulnes
Mexico City, Mexico City, Mexico, 04030